A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase of Trial: Phase I
Latest Information Update: 29 May 2018
Price : $35 *
At a glance
- Drugs Docetaxel (Primary) ; Sorafenib (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Nasopharyngeal cancer; Oropharyngeal cancer; Salivary gland cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 22 May 2018 Status changed from active, no longer recruiting to completed.
- 01 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Dec 2017.
- 27 Jul 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2016.